|By PR Newswire||
|February 3, 2014 12:30 PM EST||
SYDNEY, Feb. 3, 2014 /PRNewswire/ -- Novogen Limited (ASX: NRT; NASDAQ: NVGN), an oncology drug development company, today announced the appointments of Justine Stehn, PhD and Professor Peter Gunning, PhD to roles within the Company. Dr. Stehn and Professor Gunning are the co-inventors of the anti-tropomyosin (ATM) drug technology platform that Novogen acquired in 2013, and their appointments are an important step in realizing the significant potential of this new drug platform in treating cancer.
Novogen is focused on developing two drug technology platforms: (i) ATMs as a safer and more effective alternative to taxane chemotherapy, and (ii) its proprietary platform of super-benzopyrans, a group of small molecules with high efficacy against the full breadth of cells within a tumor, including the cancer stem cells, which have been resistant to drugs and radiation up to this point.
Dr. Stehn will hold the position of Director, ATM Program, and will have full oversight over the progress of this technology into the clinic in 2015. Professor Gunning will join the Company's Scientific Advisory Panel for ATM Technology.
"I am extremely pleased to join Novogen at a crucial period in the company's development," said Dr. Stehn. "The work we have conducted thus far in understanding ATMs leads us to believe we may have discovered a new approach to cancer therapy that could potentially offer patients a safer and more effective alternative to traditional chemotherapy, but the commonly-used taxane drugs in particular. I look forward to transitioning my work in academic research to Novogen and joining a team that is dedicated to developing new cost-effective approaches to many of the most lethal forms of cancer."
Dr. Stehn and Professor Gunning made a significant breakthrough when they discovered that the microfilament components of the cytoskeleton of cancer cells are made up largely of a particular isoform of the protein tropomyosin known as Tm5NM1. Elimination of Tm5NM1 significantly impacted the growth and survival of the cancer cell without adversely effecting normal tissue.
The first generation of drug directed against this isoform resulted in a significant anti-tumor effect in animals with human tumor xenografts (melanoma, neuroblastoma), without the collateral toxicity seen with previous compounds targeting the actin microfilaments. Their work was featured on the cover of the August (2013) edition of the journal, Cancer Research.
"I've dedicated my life's work to researching the cytoskeleton and developing treatments for children afflicted with cancer. I'm excited to become a part of Novogen as the Company moves this promising technology into the clinic in neuroblastoma, the most prevalent solid tumor in children. It is a great bonus that these drugs are likely to be equally effective against adult cancers such melanoma, ovarian and prostate cancer," said Professor Gunning.
During 2014, Novogen expects to file up to four Investigational New Drug (IND) applications with the U.S. Food and Drug Administration for its ATM technology, enabling the company to start clinical trials in 2015.
Prior to joining Novogen, Dr. Stehn was Drug Development Coordinator and group leader of the Anti-Tropomyosin Drug Development Group in Prof Gunning's Oncology Research Unit in the School of Medical Sciences at the University of New South Wales. She received her PhD from the Garvan Institute of Medical Research in 2000. She was awarded a prestigious National Health and Medical Research Council (NHMRC) CJ Martin Fellowship to support her postdoctoral positions at Harvard University and the Centre for Cancer Research at the Massachusetts Institute of Technology (MIT).
Prof. Gunning has published more than 140 research papers, and his research focuses on diseases of childhood, primarily cancer and muscle damage. He completed his PhD at Monash University on gene expression in the nervous system, and then spent nine years at Stanford University working first on neuronal differentiation and then on the regulation of the genes responsible for specifying the structure of muscle. His research group discovered that tropomyosins are used to specify the spatial and temporal properties of the cell cytoskeleton in all cells of the body.
Graham Kelly, Ph.D., Novogen Executive Director and Chief Executive Officer, said, "We are privileged to have the two inventors of this drug technology join us, and provide a considerable boost to our goal of entering the clinic with a lead candidate compound in early 2015. Their intimate knowledge of the technology, combined with our drug development experience is a very strong combination that will help us in our goal of finding new and highly effective approaches to treat many of the world's most deadly cancers."
About Anti-Tropomyosin (ATM) Drugs
ATM drugs target the tropomyosin protein component of actin microfilaments. Microfilaments, along with microtubules, form the bulk of a cell's cytoskeleton, a largely invisible structure that allows the cell to communicate internally and with neighboring cells, to move, to adhere to other cells, and to divide. Drugs targeting the cytoskeleton (micro tubular component) have been among the most widely-used drugs in oncology for over 30 years and include taxes (paclitaxel, docetaxel) and vinca alkaloids (vincristine, vinblastine). However, the range of tumor types sensitive to these drugs is limited and their action is not limited to cancer cells, with resulting dose-limiting toxicity involving the gut, bone marrow and nerves.
Novogen ATM drugs have been designed to target the Tm5NM1 isoform of tropomyosin specifically. To date, cell types such as melanoma and neuroblastoma that have a high degree of inherent insensitivity to anti-microtubular drugs (e.g. taxanes), have proved highly sensitive to ATM drugs.
About Novogen Limited
Novogen is a public, Australian biotechnology company whose shares trade on both the Australian Securities Exchange ('NRT') and NASDAQ ('NVGN'). The Company is based in Sydney, Australia, and with a U.S. office in New Haven, Connecticut. The Company has two main drug technology platforms known as super-benzopyrans (SBP) and anti-tropomyosins (ATM). SBP drugs target cancer stem cells and are being developed for the treatment of ovarian cancer and glioblastoma. ATM drugs target the cancer cell cytoskeleton and are being developed for the treatment of melanoma, prostate cancer, ovarian cancer and neuroblastoma. Novogen has entered into a joint venture with Yale University known as CanTx Inc. with the aim of developing personalized chemotherapy for patients with ovarian cancer.
Further information is available on the Company's website, www.novogen.com.
16-20 Edgeworth David Ave, Hornsby NSW 2077 AUSTRALIA
P.O. Box 2333 Hornsby Westfield NSW 1635 AUSTRALIA
 Cancer Res 73, 5169-5182 (2013). Justine R. Stehn et al. A Novel Class of Anticancer Compounds Targets the Actin Cytoskeleton in Tumor Cells.
SOURCE Novogen Limited
IoT is at the core or many Digital Transformation initiatives with the goal of re-inventing a company's business model. We all agree that collecting relevant IoT data will result in massive amounts of data needing to be stored. However, with the rapid development of IoT devices and ongoing business model transformation, we are not able to predict the volume and growth of IoT data. And with the lack of IoT history, traditional methods of IT and infrastructure planning based on the past do not app...
Jan. 20, 2017 10:45 PM EST Reads: 855
WebRTC is bringing significant change to the communications landscape that will bridge the worlds of web and telephony, making the Internet the new standard for communications. Cloud9 took the road less traveled and used WebRTC to create a downloadable enterprise-grade communications platform that is changing the communication dynamic in the financial sector. In his session at @ThingsExpo, Leo Papadopoulos, CTO of Cloud9, discussed the importance of WebRTC and how it enables companies to focus o...
Jan. 20, 2017 08:45 PM EST Reads: 4,363
"We're bringing out a new application monitoring system to the DevOps space. It manages large enterprise applications that are distributed throughout a node in many enterprises and we manage them as one collective," explained Kevin Barnes, President of eCube Systems, in this SYS-CON.tv interview at DevOps at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
Jan. 20, 2017 06:30 PM EST Reads: 5,456
The Internet of Things can drive efficiency for airlines and airports. In their session at @ThingsExpo, Shyam Varan Nath, Principal Architect with GE, and Sudip Majumder, senior director of development at Oracle, discussed the technical details of the connected airline baggage and related social media solutions. These IoT applications will enhance travelers' journey experience and drive efficiency for the airlines and the airports.
Jan. 20, 2017 05:45 PM EST Reads: 2,094
All organizations that did not originate this moment have a pre-existing culture as well as legacy technology and processes that can be more or less amenable to DevOps implementation. That organizational culture is influenced by the personalities and management styles of Executive Management, the wider culture in which the organization is situated, and the personalities of key team members at all levels of the organization. This culture and entrenched interests usually throw a wrench in the work...
Jan. 20, 2017 05:30 PM EST Reads: 1,478
In his General Session at DevOps Summit, Asaf Yigal, Co-Founder & VP of Product at Logz.io, will explore the value of Kibana 4 for log analysis and will give a real live, hands-on tutorial on how to set up Kibana 4 and get the most out of Apache log files. He will examine three use cases: IT operations, business intelligence, and security and compliance. This is a hands-on session that will require participants to bring their own laptops, and we will provide the rest.
Jan. 20, 2017 05:15 PM EST Reads: 4,956
With major technology companies and startups seriously embracing IoT strategies, now is the perfect time to attend @ThingsExpo 2016 in New York. Learn what is going on, contribute to the discussions, and ensure that your enterprise is as "IoT-Ready" as it can be! Internet of @ThingsExpo, taking place June 6-8, 2017, at the Javits Center in New York City, New York, is co-located with 20th Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry p...
Jan. 20, 2017 05:15 PM EST Reads: 3,806
@DevOpsSummit at Cloud taking place June 6-8, 2017, at Javits Center, New York City, is co-located with the 20th International Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The widespread success of cloud computing is driving the DevOps revolution in enterprise IT. Now as never before, development teams must communicate and collaborate in a dynamic, 24/7/365 environment. There is no time to wait for long developm...
Jan. 20, 2017 05:15 PM EST Reads: 3,536
A look across the tech landscape at the disruptive technologies that are increasing in prominence and speculate as to which will be most impactful for communications – namely, AI and Cloud Computing. In his session at 20th Cloud Expo, Curtis Peterson, VP of Operations at RingCentral, will highlight the current challenges of these transformative technologies and share strategies for preparing your organization for these changes. This “view from the top” will outline the latest trends and developm...
Jan. 20, 2017 04:45 PM EST Reads: 1,082
"LinearHub provides smart video conferencing, which is the Roundee service, and we archive all the video conferences and we also provide the transcript," stated Sunghyuk Kim, CEO of LinearHub, in this SYS-CON.tv interview at @ThingsExpo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
Jan. 20, 2017 03:00 PM EST Reads: 1,654
When you focus on a journey from up-close, you look at your own technical and cultural history and how you changed it for the benefit of the customer. This was our starting point: too many integration issues, 13 SWP days and very long cycles. It was evident that in this fast-paced industry we could no longer afford this reality. We needed something that would take us beyond reducing the development lifecycles, CI and Agile methodologies. We made a fundamental difference, even changed our culture...
Jan. 20, 2017 02:30 PM EST Reads: 1,130
Things are changing so quickly in IoT that it would take a wizard to predict which ecosystem will gain the most traction. In order for IoT to reach its potential, smart devices must be able to work together. Today, there are a slew of interoperability standards being promoted by big names to make this happen: HomeKit, Brillo and Alljoyn. In his session at @ThingsExpo, Adam Justice, vice president and general manager of Grid Connect, will review what happens when smart devices don’t work togethe...
Jan. 20, 2017 02:15 PM EST Reads: 627
The 20th International Cloud Expo has announced that its Call for Papers is open. Cloud Expo, to be held June 6-8, 2017, at the Javits Center in New York City, brings together Cloud Computing, Big Data, Internet of Things, DevOps, Containers, Microservices and WebRTC to one location. With cloud computing driving a higher percentage of enterprise IT budgets every year, it becomes increasingly important to plant your flag in this fast-expanding business opportunity. Submit your speaking proposal ...
Jan. 20, 2017 01:30 PM EST Reads: 5,239
@DevOpsSummit taking place June 6-8, 2017 at Javits Center, New York City, is co-located with the 20th International Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. @DevOpsSummit at Cloud Expo New York Call for Papers is now open.
Jan. 20, 2017 01:30 PM EST Reads: 3,598
"There's a growing demand from users for things to be faster. When you think about all the transactions or interactions users will have with your product and everything that is between those transactions and interactions - what drives us at Catchpoint Systems is the idea to measure that and to analyze it," explained Leo Vasiliou, Director of Web Performance Engineering at Catchpoint Systems, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York Ci...
Jan. 20, 2017 01:30 PM EST Reads: 5,734